

SYNCOR INTERNATIONAL CORP /DE/
Form DEFA14A
November 25, 2002

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 14a

Proxy Statement Pursuant to Section 14(a) of the Securities
Exchange Act of 1934 (Amendment No.)

Filed by the Registrant [X]
Filed by a Party other than the Registrant []

Check the appropriate box:

- Preliminary Proxy Statement
- Confidential, for Use of the Commission Only
(as permitted by Rule 14a-6(e)(2))
- Definitive Proxy Statement
- Definitive Additional Materials
- Soliciting Material Pursuant to Section 240.14a-12

SYNCOR INTERNATIONAL CORPORATION

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

- No fee required.
- Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
 - 1) Title of each class of securities to which transaction applies:
 - 2) Aggregate number of securities to which transaction applies:
 - 3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
 - 4) Proposed maximum aggregate value of transaction:
 - 5) Total fee paid:
- Fee paid previously with preliminary materials.
- Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
 - 1) Amount Previously Paid:

Edgar Filing: SYNCOR INTERNATIONAL CORP /DE/ - Form DEFA14A

- 2) Form, Schedule or Registration Statement No.:
- 3) Filing Party:
- 4) Date Filed:

[SYNCOR LOGO]

November 25, 2002

Dear Stockholder:

We are writing to advise you that the special meeting of stockholders of Syncor International Corporation that was originally scheduled to be held on Tuesday, November 19, 2002, has been postponed and will now be held at 10:00 a.m., California time, on December 6, 2002, at the Warner Center Hilton Hotel, 6360 Canoga Avenue in Woodland Hills, California. However, Syncor currently intends to convene the special meeting solely for the purpose of adjourning the meeting to a later time, date and place so that certain additional information can be provided to stockholders.

On October 17, 2002, Syncor mailed a Notice of Special Meeting and Proxy Statement, which we refer to as the original proxy statement, to stockholders of record for a special meeting of stockholders which was originally scheduled to be held on November 19, 2002, for the purpose of, among other things, voting on the proposed merger agreement with Cardinal Health. Subsequent to the date of the original proxy statement, Syncor announced that a committee of outside directors, together with outside counsel, has been investigating the propriety of certain payments made by international subsidiaries of Syncor to customers in several foreign countries. Additionally, subsequent to the date of the original proxy statement, Syncor and Cardinal Health announced that Cardinal Health has initiated discussions with Syncor regarding the possible modification of the terms of the merger agreement. In order to provide the parties with the opportunity to continue these discussions, Cardinal Health and Syncor have amended the merger agreement to extend the date after which either party may unilaterally elect to terminate the transaction from December 31, 2002 to January 15, 2003, subject to the terms of the merger agreement. While the parties intend to continue these discussions, there can be no assurance that such discussions will result in the parties agreeing to any revised terms.

In light of these developments, and in order to provide time so that additional information regarding the investigation and related matters and any possible modification to the terms of the merger agreement may be provided to stockholders, Syncor currently intends to convene the postponed special meeting on December 6, 2002 solely for the purpose of adjourning the meeting to a later time, date and place. It is currently anticipated that the new time, date and place of the adjourned special meeting will be disclosed in a press release and in supplemental proxy materials to be mailed to stockholders, as well as announced at the postponed meeting on December 6, 2002.

Included with this letter is (1) a supplemental notice of postponed meeting, (2) a copy of a press release issued by Syncor on November 19, 2002 disclosing Syncor's third quarter financial results and the status of the special committee's investigation, (3) a copy of a joint press release issued by Syncor and Cardinal Health on November 21, 2002 disclosing that Cardinal Health has initiated discussions with Syncor regarding the possible modification of the terms of the merger agreement, (4) a copy of a joint press release issued by Syncor and Cardinal Health on November 22, 2002 disclosing that the parties

Edgar Filing: SYNCOR INTERNATIONAL CORP /DE/ - Form DEFA14A

extended the termination date of the merger agreement and (5) a duplicate copy of a proxy card to be used for voting your shares at the special meeting.

If you have not already voted or wish to change your vote, you may do so on the enclosed proxy card or via the internet or telephone. We appreciate your continued loyalty and support.

Cordially,

/s/ Bernard Puckett
BERNARD PUCKETT
Lead Director of the Board

/s/ Robert G. Funari
ROBERT G. FUNARI
President and Chief Executive Officer

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of the securities to be issued or determined if this document is truthful or complete. Any representation to the contrary is a criminal offense. This document does not constitute an offer to sell or a solicitation of an offer to buy any securities in any jurisdiction where an offer or solicitation would be illegal.

This document is dated and is first being mailed to stockholders on or about November 25, 2002.

SYNCOR INTERNATIONAL CORPORATION

SUPPLEMENTAL NOTICE OF POSTPONEMENT
OF SPECIAL MEETING OF STOCKHOLDERS

To the Stockholders of Syncor:

The special meeting of the stockholders of Syncor International Corporation, a Delaware corporation, has been postponed from Tuesday, November 19, 2002, to Friday, December 6, 2002. The postponed special meeting will be held at 10:00 a.m., California time, December 6, 2002, at the Warner Center Hilton Hotel, 6360 Canoga Avenue in Woodland Hills, California. The purposes of the special meeting are to:

1. Vote on a proposal to approve the Agreement and Plan of Merger, dated as of June 14, 2002, among Cardinal Health, Inc., Mudhen Merger Corp., a wholly owned subsidiary of Cardinal Health, and Syncor. Pursuant to the merger agreement, Mudhen Merger Corp. will merge with and into Syncor upon the terms and subject to the conditions set forth in the merger agreement, as more fully described in the Notice of Special Meeting and Proxy Statement mailed to you on or about October 17, 2002, which we refer to as the original proxy statement. If the merger agreement is approved and the merger and the related transactions contemplated by the merger agreement are consummated, each share of Syncor common stock will become 0.52 of a Cardinal Health common share.
2. Adjourn the special meeting, if necessary, to permit further solicitation of proxies in the event there are not sufficient votes at the time of the special meeting to approve the merger agreement proposal.
3. Act on any other matters that may properly come before the special meeting.

Edgar Filing: SYNCOR INTERNATIONAL CORP /DE/ - Form DEFA14A

Your board of directors has fixed the close of business on October 9, 2002, as the record date for determining stockholders entitled to notice of and to vote at the special meeting. The merger agreement proposal requires the affirmative vote of the holders of a majority of the outstanding Syncor shares entitled to vote on the merger agreement proposal. Stockholders owning approximately 6.8% of the outstanding Syncor shares as of the record date already have agreed in writing to vote in favor of the approval of the merger agreement proposal.

Syncor currently intends to convene the special meeting solely for the purpose of adjourning the meeting to a later time, date and place so that certain additional information can be provided to stockholders.

Enclosed is a duplicate copy of a proxy card. The proxy card which accompanied the original proxy statement will remain valid. If you already returned the original proxy card, your votes will be recorded unless you submit a subsequent proxy changing your vote or you revoke your proxy. If you have not voted or wish to change your vote, please mark, date and execute the enclosed duplicate proxy card and mail it promptly in the enclosed envelope. Additional instructions regarding voting and revocation of proxies is contained on page 19 of the original proxy statement.

By Order of the Board of Directors

/s/ Edwin A. Burgos
EDWIN A. BURGOS
Secretary

November 25, 2002
Woodland Hills, California

[SYNCOR LOGO]

NASDAQ: SCOR

FOR IMMEDIATE RELEASE

CONTACT:
Allan Mayer
Sitrick And Company
(310) 788-2850

William Powell
Syncor International
Corp.
(818) 737-4702

SYNCOR FILES FORM 10-Q AND REPORTS
STRONG THIRD-QUARTER FINANCIAL RESULTS
FOR ITS U.S. PHARMACY SERVICES BUSINESS

COMPANY REPORTS ON STATUS OF SPECIAL COMMITTEE INVESTIGATION

WOODLAND HILLS, CALIFORNIA, NOVEMBER 19, 2002 -- Syncor International Corporation (Nasdaq: SCOR) today announced that it has filed with the SEC its Form 10-Q for the quarter ended September 30, 2002. The filing shows a 28 percent increase in net sales from continuing operations and a 53 percent increase in operating income of its core U.S. pharmacy services business from the same period last year.

Edgar Filing: SYNCOR INTERNATIONAL CORP /DE/ - Form DEFA14A

According to the 10-Q, Syncor's net sales from continuing operations in the quarter increased 28.3 percent to \$192.2 million, compared to \$149.8 million for the same period of the prior year.

The Company generated sufficient cash flow during the quarter to repay Company debt in the amount of \$12 million.

U.S. PHARMACY SERVICES BUSINESS

For the third quarter ended September 30, 2002, sales increased by 28.0 percent to \$181.9 million, compared to \$142.1 million for the same period of the prior year. Syncor continues to realize strong Cardiolite(R) sales, which increased 22.3 percent as compared to the same period of the prior year due to improved pricing as well as volume increases.

Operating income for the third quarter of 2002 increased by 53.3 percent to \$23.9 million, compared to \$15.6 million for the same period of the prior year.

SPECIAL CHARGES

As previously reported as a subsequent event in our Form 10-K/A-1 for the year ended December 31, 2001 and our Forms 10-Q/A-1 for the quarters ended March 31, 2002 and June 30, 2002, each filed with the SEC on October 11, 2002, the Company recorded a special charge to earnings net after-tax of \$31.3 million or (\$1.14) per fully diluted share in the third quarter ended September 30, 2002. The Company took the asset impairment charge based on its review of the offers it received from potential buyers for Comprehensive Medical Imaging, Inc. (CMI), the Company's discontinued medical imaging segment, and the Company's assessment of the probable loss to the Company upon the sale of CMI. The Company announced on June 14, 2002 that it is discontinuing the CMI operations and is entertaining bids for the sale of CMI.

Syncor International Corporation

SYNCOR FILES FORM 10-Q AND REPORTS
STRONG THIRD QUARTER FINANCIAL RESULTS
FOR ITS U.S. PHARMACY SERVICES BUSINESS
November 19, 2002
Page 2

UPDATE ON SPECIAL COMMITTEE INVESTIGATION AND DISCUSSIONS WITH THE DOJ AND SEC

As reported in the Form 10-Q, a special committee of the Board of Directors of Syncor, working together with outside counsel and an independent forensic accounting firm, believes it has substantially completed its gathering of facts in connection with the previously-announced investigation of all of Syncor's foreign operations (other than Israel where Syncor has only a licensing arrangement and no operations). The special committee also is investigating certain limited aspects of Syncor's domestic U.S. operations. The investigation has included on-site reviews by representatives of the special committee in every foreign country in which Syncor has operations. The special committee is also investigating the knowledge and/or involvement of certain employees of Syncor and its subsidiaries, including Monty Fu and Moses Fu, in the matters subject to the investigation. Analysis of the information gathered is continuing.

The following is a summary of the findings of the special committee to date based on the information it has gathered at this time. The investigation is continuing and there can be no assurance that additional issues will not be found or that the findings below will be confirmed.

- The special committee has found that questionable payments have been made

Edgar Filing: SYNCOR INTERNATIONAL CORP /DE/ - Form DEFA14A

over a substantial period of time to customers in Taiwan, including state-owned and private healthcare facilities and certain of their employees. Based on information gathered to date, some or all of the payments appear to have violated U.S. law, including various provisions of the Foreign Corrupt Practices Act of 1977 (the "FCPA"). In addition, some or all of the payments appear to have violated local Taiwan law. Over the past five years, these payments to state-owned facilities and certain of their employees appear to have totaled an estimated \$500,000.

- The special committee has also found questionable payments and other transactions at Syncor operations in at least six other countries in Asia, Latin America and Europe that also may have violated U.S. law, including the payment, record-keeping and controls provisions of the FCPA. In addition, some or all of these payments appear to have violated local laws in the relevant jurisdiction.
- During the course of its investigation of Syncor's foreign operations, the special committee identified a number of additional instances where activities of Syncor or of its subsidiaries or representatives may have constituted violations of local laws and regulations relating to, among other things, tax, competition and regulatory matters.

While the special committee and its advisors are continuing the investigation, based on the information available at this time, Syncor does not expect that any of these payments, transactions or other matters will be material to the financial results of Syncor or will result in an adjustment or restatement of Syncor's historical financial statements. The special committee intends to complete the investigation as promptly as practicable. A final determination as to the full impact of the investigation on Syncor and Syncor's financial statements is subject to the completion of the investigation.

Syncor has been cooperating fully with the Securities and Exchange Commission (the "SEC") and the U.S. Department of Justice (the "DOJ") regarding the matters that have been the subject of its internal investigation. At this time, Syncor is in advanced discussions with the SEC staff concerning resolution of the potential claims that the SEC may have against Syncor regarding the matters that are the subject of the investigation. Any resolution with the staff would be subject to SEC approval. Syncor is also in advanced discussions with the DOJ concerning a resolution of these matters. Syncor is seeking to resolve these matters with the SEC and the DOJ as promptly as practicable although there can be no assurance that such discussions will result in a satisfactory resolution of these matters. At this time Syncor cannot predict the extent to which the SEC, the DOJ or any other governmental authorities will pursue administrative, civil injunctive or criminal proceedings, the imposition of fines or penalties or other remedies or sanctions.

Syncor International Corporation

SYNCOR FILES FORM 10-Q AND REPORTS
STRONG THIRD QUARTER FINANCIAL RESULTS
FOR ITS U.S. PHARMACY SERVICES BUSINESS
November 19, 2002
Page 3

However, based on the current status of the discussions with the SEC and the DOJ, Syncor has accrued \$2.5 million for estimated potential fines and other penalties that may be imposed by the SEC and the DOJ in connection with this matter. There can be no assurance that this reserve will be sufficient to address any such fines or other penalties actually imposed by the SEC, the DOJ or any other governmental authorities. At this time, Syncor also cannot predict what impact such discussions with or actions by the SEC, the DOJ or any other governmental authorities may have on Syncor.

Edgar Filing: SYNCOR INTERNATIONAL CORP /DE/ - Form DEFA14A

Additional information is included in the Form 10-Q and you are urged to read the relevant disclosure in its entirety.

ACQUISITION OF SYNCOR BY CARDINAL HEALTH

On June 14, 2002, the Company announced that it had entered into a definitive agreement with Cardinal Health providing for the acquisition of Syncor. As previously announced, Syncor has postponed its special meeting of stockholders, which is now scheduled for December 6, 2002, to consider approval of the merger agreement. The exact time and place of the postponed special meeting will be included in an amended notice of meeting and supplemental proxy materials that will be mailed to stockholders as soon as they are available.

The acquisition of Syncor by Cardinal Health is subject to the satisfaction or waiver of a number of conditions, including Syncor stockholder approval. Based on the information Syncor has reviewed as of the date hereof with respect to the matters currently under investigation by the special committee, and subject to the terms of any resolution of these matters with the DOJ and SEC, Syncor believes that the information it has learned in the investigation would not result in Syncor's failure to satisfy the conditions to the acquisition. However, no definitive determination as to the impact on the acquisition can be made pending completion of the investigation and resolution of Syncor's discussions with the DOJ and SEC. Moreover, Cardinal Health has previously stated that it has not yet concluded whether the conditions to the transaction will be satisfied and that "there can be no assurance that the transaction involving the acquisition of Syncor by Cardinal Health will be completed."

ABOUT SYNCOR

SYNCOR INTERNATIONAL CORPORATION is a leading provider of high technology health care services concentrating on nuclear pharmacy services, medical imaging, niche manufacturing and radiotherapy. In the nuclear pharmacy services business, Syncor compounds and dispenses radiopharmaceuticals for diagnostic and therapeutic use by nuclear medicine departments in hospitals and outpatient clinics. Syncor distributes these time-critical pharmaceuticals to more than 7,000 U.S.-based customers through an integrated network of 130 domestic and 19 international nuclear pharmacies. Medical imaging services are provided through an integrated network of 73 domestic and 19 internationally owned or operated facilities. Syncor announced on June 14, 2002 that it intends to exit the U.S. medical imaging business. Syncor also owns or operates ten domestic and two international production facilities for positron emission tomography (PET) radiopharmaceuticals, and is a party to a series of agreements to make PET technology more accessible to healthcare providers and patients nationwide. For more information visit www.syncor.com.

Syncor International Corporation

SYNCOR FILES FORM 10-Q AND REPORTS
STRONG THIRD QUARTER FINANCIAL RESULTS
FOR ITS U.S. PHARMACY SERVICES BUSINESS
November 19, 2002
Page 4

Except for historical information, all other information in this news release consists of forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, anticipated or implied. The most significant of these uncertainties are described in Syncor's Form 10-K, Form 8-K and Form 10-Q

Edgar Filing: SYNCOR INTERNATIONAL CORP /DE/ - Form DEFA14A

reports (including all amendments to those reports) and exhibits to those reports, and include (but are not limited to) the costs, difficulties, and uncertainties related to the integration of acquired businesses, the loss of one or more key customer or supplier relationships, changes in the distribution patterns or reimbursement rates for health-care products and/or services, the costs and other effects of governmental regulation and legal and administrative proceedings, and general economic and market conditions. Syncor undertakes no obligation to update or revise any forward-looking statements.

Information regarding the identity of the persons who may, under SEC rules, be deemed to be participants in the solicitation of stockholders of Syncor International Corporation ("Syncor") in connection with the proposed merger, and their interests in the solicitation, is set forth in the definitive proxy statement/prospectus dated October 16, 2002 mailed to Syncor shareholders on October 17, 2002 and filed with the SEC. Cardinal Health, Inc. ("Cardinal Health") has filed a registration statement on Form S-4 in connection with the transaction. Investors and security holders of Syncor are urged to read the definitive proxy statement/prospectus because it contains important information about Cardinal Health, Syncor and the transaction. Investors and security holders may obtain a free copy of the proxy statement/prospectus at the SEC's web site at www.sec.gov. A free copy of the proxy statement/prospectus may also be obtained from Cardinal Health or Syncor. Cardinal Health and Syncor and their respective executive officers and directors may be deemed to be participants in the solicitation of proxies from the stockholders of Syncor in favor of the transaction. In addition to the registration statement on Form S-4 filed by Cardinal Health in connection with the transaction, and the proxy statement/prospectus mailed to the stockholders of Syncor in connection with the transaction, each of Cardinal and Syncor file annual, quarterly and special reports, proxy and information statements, and other information with the SEC. Investors may read and copy any of these reports, statements and other information at the SEC's public reference room located at 450 5th Street, N.W., Washington, D.C., 20549. Investors should call the SEC at 1-800-SEC-0330 for further information. The reports, statements and other information filed by Cardinal Health and Syncor with the SEC are also available for free at the SEC's web site at www.sec.gov. A free copy of these reports, statements and other information may also be obtained from Cardinal Health or Syncor. Investors should read the proxy statement/prospectus carefully before making any voting or investment decision.

#

SYNCOR INTERNATIONAL CORPORATION THREE MONTHS ENDED SEPTEMBER 30, 2002

	Q3 2002 ACTUAL	Q3 2001 ACTUAL	% CHANGE
	(\$ IN 000'S)		
Net Sales.....	\$192,212	\$149,818	28.3%
Less: Cost of Goods Sold.....	133,458	105,009	27.1%
GROSS PROFIT.....	58,754	44,809	31.1%
% of Sales.....	30.6%	29.9%	
Operating, Selling and Admin. Expenses.....	39,834	29,506	35.0%
Depreciation Expense.....	5,007	4,391	14.0%
Special Charges:			

Edgar Filing: SYNCOR INTERNATIONAL CORP /DE/ - Form DEFA14A

Transaction Costs.....	2,270	--	--
	-----	-----	
Total Operating Expenses.....	47,111	33,897	39.0%
% of Sales.....	24.5%	22.6%	
OPERATING INCOME.....	11,643	10,912	6.7%
% of Sales.....	6.1%	7.3%	
Other Income (Expense), net.....	(2,114)	595	--
	-----	-----	
Income From Continuing Operations.....	9,529	11,507	-17.2%
Income Taxes.....	5,870	4,432	32.4%
	-----	-----	
Income From Continuing Operations After Tax.....	3,659	7,075	-48.3%
Discontinued Operations, net of taxes.....	(32,150)	759	--
	-----	-----	
NET INCOME (LOSS), NET OF TAXES.....	\$ (28,491)	\$ 7,834	--
	=====	=====	
% of Sales.....	-14.8%	5.2%	
Basic Earnings (Loss) per Common Share:			
Continuing Operations.....	\$ 0.14	\$ 0.29	
Discontinued Operations.....	\$ (1.25)	\$ 0.03	
	-----	-----	
Net Basic Earnings (Loss) per Common Share.....	\$ (1.11)	\$ 0.32	
	=====	=====	
Diluted Earnings (Loss) per Common Share:			
Continuing Operations.....	\$ 0.13	\$ 0.26	
Discontinued Operations.....	\$ (1.17)	\$ 0.03	
	-----	-----	
Net Diluted Earnings (Loss) per Common Share.....	\$ (1.04)	\$ 0.29	
	=====	=====	
Weighted Average Number of Common Shares Outstanding:			
Basic.....	25,695	24,603	
Diluted.....	27,405	27,024	

SYNCOR INTERNATIONAL CORPORATION
NINE MONTHS ENDED SEPTEMBER 30, 2002

	YTD Q3 2002 ACTUAL	YTD Q3 2001 ACTUAL	% CHANGE
	-----	-----	-----
	(\$ IN 000'S)		
Net Sales.....	\$555,112	\$434,288	27.8%
	-----	-----	
Less: Cost of Goods Sold.....	380,760	303,203	25.6%
	-----	-----	
GROSS PROFIT.....	174,352	131,085	33.0%
	-----	-----	
% of Sales.....	31.4%	30.2%	
Operating, Selling and Admin. Expenses.....	109,202	74,859	45.9%
Depreciation Expense.....	14,609	11,713	24.7%
Special Charges:			
Severance Expense.....	4,125	--	--
Transaction Costs.....	3,136	--	--
	-----	-----	
Total Operating Expenses.....	131,072	86,572	51.4%
% of Sales.....	23.6%	19.9%	
OPERATING INCOME.....	43,280	44,513	-2.8%
% of Sales.....	7.8%	10.2%	

Edgar Filing: SYNCOR INTERNATIONAL CORP /DE/ - Form DEFA14A

Other Income (Expense), net.....	(3,029)	(912)	--
	-----	-----	
Income From Continuing Operations.....	40,251	43,601	-7.7%
Income Taxes.....	17,697	16,858	5.0%
	-----	-----	
Income From Continuing Operations After Tax.....	22,554	26,743	-15.7%
Discontinued Operations, net of taxes.....	(55,131)	2,280	--
	-----	-----	
NET INCOME (LOSS), NET OF TAXES.....	\$ (32,577)	\$ 29,023	--
	=====	=====	
% of Sales.....	-5.9%	6.7%	
Basic Earnings (Loss) per Common Share:			
Continuing Operations.....	\$ 0.90	\$ 1.09	
Discontinued Operations.....	\$ (2.20)	\$ 0.09	
	-----	-----	
Net Basic Earnings (Loss) per Common Share.....	\$ (1.30)	\$ 1.18	
	=====	=====	
Diluted Earnings (Loss) per Common Share:			
Continuing Operations.....	\$ 0.83	\$ 0.99	
Discontinued Operations.....	\$ (2.04)	\$ 0.08	
	-----	-----	
Net Diluted Earnings (Loss) per Common Share.....	\$ (1.21)	\$ 1.07	
	=====	=====	
Weighted Average Number of Common Shares Outstanding:			
Basic.....	25,081	24,494	
Diluted.....	26,993	27,047	

SYNCOR INTERNATIONAL CORPORATION

SEGMENT OPERATING RESULTS FROM CONTINUING OPERATIONS

FOR THE THREE MONTHS ENDED SEPTEMBER 30,

	SPS			OVERSEAS		
	Q3 2002	Q3 2001	% CHANGE	Q3 2002	Q3 2001	% CHANGE

	(\$ IN 000'S)					

Net Sales.....	\$181,877	\$142,101	28.0%	\$10,335	\$7,717	33.9%
Cost of Sales.....	126,582	100,710	25.7%	6,876	4,299	59.9%
	-----	-----		-----	-----	
Gross Profit.....	55,295	41,391	33.6%	3,459	3,418	1.2%
% of Net Sales.....	30.4%	29.1%		33.5%	44.3%	
Operating, Selling and						
Administrative Expenses.....	28,863	23,834	21.1%	3,889	2,513	54.8%
Depreciation & Amortization.....	2,538	1,970	28.8%	882	1,096	-19.5%
	-----	-----		-----	-----	
Total Expenses.....	31,401	25,804	21.7%	4,771	3,609	32.2%
	-----	-----		-----	-----	
% of Net Sales.....	17.3%	18.2%		46.2%	46.8%	
Operating Income (Loss).....	\$ 23,894	\$ 15,587	53.3%	\$ (1,312)	\$ (191)	100%
	=====	=====		=====	=====	
% of Net Sales.....	13.1%	11.0%		-12.7%	-2.5%	

Edgar Filing: SYNCOR INTERNATIONAL CORP /DE/ - Form DEFA14A

Note -- the totals from this schedule will not agree to Syncor's Consolidated Statements of Income due to Unallocated Corporate expenses

Reclassifications -- certain items have been reclassified in Q3 2001 business unit results to conform to the current year's presentation; there is not an impact on overall consolidated operating results.

SYNCOR INTERNATIONAL CORPORATION

SEGMENT OPERATING RESULTS FROM CONTINUING OPERATIONS

	FOR THE NINE MONTHS ENDED SEPTEMBER 30,					
	SPS			OVERSEAS		
	YTD Q3 2002	YTD Q3 2001	% CHANGE	YTD Q3 2002	YTD Q3 2001	%
	(\$ IN 000'S)					
Net Sales.....	\$524,004	\$412,941	26.9%	\$31,108	\$21,347	
Cost of Sales.....	360,918	290,804	24.1%	19,842	12,399	
Gross Profit.....	163,086	122,137	33.5%	11,266	8,948	
% of Net Sales.....	31.1%	29.6%		36.2%	41.9%	
Operating, Selling and Administrative Expenses.....	83,016	60,470	37.3%	9,718	6,627	
Depreciation & Amortization.....	7,227	5,160	40.1%	2,442	2,574	
Total Expenses.....	90,243	65,630	37.5%	12,160	9,201	
% of Net Sales.....	17.2%	15.9%		39.1%	43.1%	
Operating Income (Loss)....	\$ 72,843	\$ 56,507	28.9%	\$ (894)	\$ (253)	
% of Net Sales.....	13.9%	13.7%		-2.9%	-1.2%	

Note -- the totals from this schedule will not agree to Syncor's Consolidated Statements of Income due to Unallocated Corporate expenses

Reclassifications -- certain items have been reclassified in Q3 2001 business unit results to conform to the current year's presentation; there is not an impact on overall consolidated operating results.

SYNCOR INTERNATIONAL CORPORATION

PRO FORMA FINANCIAL STATEMENTS
THREE MONTHS ENDED SEPTEMBER 30, 2002

AS REPORTED

DISCONTINUED OPERATIONS

Edgar Filing: SYNCOR INTERNATIONAL CORP /DE/ - Form DEFA14A

	BEFORE	CORPORATE CHARGES	CORPORATE CHARGES	TOTAL	RESTRUCTURING AND OTHER CHARGE			T
	CHARGES				SEEDS	OVERSEAS	IMAGING	
(\$ IN 000'S)								
Net Sales.....	\$192,212		\$ 0	\$192,212	\$ 0	\$ 0	\$ 0	\$
Cost of Sales.....	133,458		--	133,458	--	--	--	
Gross Profit.....	58,754		--	58,754	--	--	--	
Operating, Selling and Admin.	39,834		--	39,834	--	--	--	
Depreciation Expense.....	5,007		--	5,007	--	--	--	
Transaction Costs.....	--		2,270	2,270	--	--	--	
Total Operating Expenses.....	44,841		2,270	47,111	--	--	--	
Operating Income (Loss)...	13,913		(2,270)	11,643	--	--	--	
Other Income (Expense), Net.....	386		(2,500)	(2,114)	--	--	(47,519)	(
Operating Income (Loss)...	14,299		(4,770)	9,529	--	--	(47,519)	(
Income Taxes (Benefit)....	5,597		273	5,870	--	--	(16,204)	(
Income (Loss) After Tax...	\$ 8,702		\$ (5,043)	\$ 3,659	\$ 0	\$ 0	\$ (31,315)	\$ (
Fully Diluted Outstanding Shares.....	27,405		27,405	27,405	27,405	27,405	27,405	
Diluted Earnings (Loss) Per Common Share.....	\$ 0.31		\$ (0.18)	\$ 0.13	\$ 0.00	\$ 0.00	\$ (1.14)	\$

DISCONTINUED OPERATIONS

RESULTS FOR THREE MONTHS ENDED SEPTEMBER 30, 2002					
	SEEDS	OVERSEAS	IMAGING	TOTAL	COMBINED
(\$ IN 000'S)					
Net Sales.....	\$ 0	\$ 1,574	\$39,894	\$41,468	\$ 41,468
Cost of Sales.....	--	977	13,705	14,682	14,682
Gross Profit.....	--	597	26,189	26,786	26,786
Operating, Selling and Admin.	--	579	18,045	18,624	18,624
Depreciation Expense.....	--	107	5,598	5,705	5,705
Transaction Costs.....	--	--	--	--	--
Total Operating Expenses.....	--	686	23,643	24,329	24,329
Operating Income (Loss)...	--	(89)	2,546	2,457	2,457
Other Income (Expense),					

Edgar Filing: SYNCOR INTERNATIONAL CORP /DE/ - Form DEFA14A

Net.....	--	(175)	(3,027)	(3,202)	(50,721)
Operating Income (Loss)...	--	(264)	(481)	(745)	(48,264)
Income Taxes (Benefit)....	--	17	73	90	(16,114)
Income (Loss) After Tax...	\$ 0	\$ (281)	\$ (554)	\$ (835)	\$ (32,150)
Fully Diluted Outstanding Shares.....	--	27,405	27,405	27,405	27,405
Diluted Earnings (Loss) Per Common Share.....	\$0.00	\$ (0.01)	\$ (0.02)	\$ (0.03)	\$ (1.17)

Note: We have included this schedule to provide more detail of the non-recurring expenses for the period presented and to provide the detail of the restructuring charges and discontinued operations. Included in the As Reported columns is a reconciliation of the reported results of operations and the non-recurring charges for the period. For the discontinued operations we have shown a reconciliation of the components of the discontinued operations breaking out the non-recurring charges from the discontinued operations results for the period.

SYNCOR INTERNATIONAL CORPORATION

PRO FORMA FINANCIAL STATEMENTS
NINE MONTHS ENDED SEPTEMBER 30, 2002

	AS REPORTED			DISCONTINUED OPERATIONS		
	BEFORE CORPORATE CHARGES	CORPORATE CHARGES	TOTAL	RESTRUCTURING AND OTHER SEEDS	OVERSEAS	IMAGING
	(\$ IN 000'S)					
Net Sales.....	\$555,112	\$ 0	\$555,112	\$ 0	\$ 0	\$ (2,37)
Cost of Sales.....	380,760	--	380,760	--	--	--
Gross Profit.....	174,352	--	174,352	--	--	(2,37)
Operating, Selling and Admin.	109,202	--	109,202	--	--	98
Depreciation Expense.....	14,609	--	14,609	--	--	--
Severance Costs.....	--	3,604	3,604	125	1,685	6,00
Transaction Costs.....	--	3,136	3,136	--	--	--
Asset Impairment or write downs.....	--	521	521	702	13,484	8,78
Total Operating Expenses.....	123,811	7,261	131,072	827	15,169	15,77
Operating Income (Loss).....	50,541	(7,261)	43,280	(827)	(15,169)	(18,14)
Other Income (Expense), Net.....	(529)	(2,500)	(3,029)	--	--	(47,51)
Operating Income (Loss).....	50,012	(9,761)	40,251	(827)	(15,169)	(65,66)

Edgar Filing: SYNCOR INTERNATIONAL CORP /DE/ - Form DEFA14A

Income Taxes (Benefit).....	19,346	(1,649)	17,697	(318)	(2,003)	(23,19)
Income (Loss) After Tax.....	\$ 30,666	\$ (8,112)	\$ 22,554	\$ (509)	\$ (13,166)	\$ (42,47)
Fully Diluted Outstanding Shares.....	26,993	26,993	26,993	26,993	26,993	26,99
Diluted Earnings (Loss) Per Common Share.....	\$ 1.13	\$ (0.30)	\$ 0.83	\$ (0.02)	\$ (0.49)	\$ (1.5)

DISCONTINUED OPERATIONS

RESULTS FOR NINE MONTHS ENDED
SEPTEMBER 30, 2002

	SEEDS	OVERSEAS	IMAGING	TOTAL	COMBINED
	(\$ IN 000'S)				
Net Sales.....	\$ 120	\$ 4,817	\$120,970	\$125,907	\$123,531
Cost of Sales.....	180	3,053	40,339	43,572	43,572
Gross Profit.....	(60)	1,764	80,631	82,335	79,959
Operating, Selling and Admin.	95	1,946	53,083	55,124	56,111
Depreciation Expense.....	21	546	16,005	16,572	16,572
Severance Costs.....					7,812
Transaction Costs.....					--
Asset Impairment or write downs.....	--	--	--	--	22,970
Total Operating Expenses.....	116	2,492	69,088	71,696	103,465
Operating Income (Loss).....	(176)	(728)	11,543	10,639	(23,506)
Other Income (Expense), Net.....	--	83	(8,448)	(8,365)	(55,884)
Operating Income (Loss).....	(176)	(645)	3,095	2,274	(79,390)
Income Taxes (Benefit).....	(68)	(130)	1,451	1,253	(24,259)
Income (Loss) After Tax.....	\$ (108)	\$ (515)	\$ 1,644	\$ 1,021	\$ (55,131)
Fully Diluted Outstanding Shares.....	26,993	26,993	26,993	26,993	26,993
Diluted Earnings (Loss) Per Common Share.....	\$ (0.00)	\$ (0.02)	\$ 0.06	\$ 0.04	\$ (2.04)

Note: We have included this schedule to provide more detail of the non-recurring expenses for the period presented and to provide the detail of the restructuring charges and discontinued operations. Included in the As Reported columns is a reconciliation of the reported results of operations and the non-recurring charges for the period. For the discontinued operations we have shown a reconciliation of the components of the discontinued operations breaking out the non-recurring charges from the

Edgar Filing: SYNCOR INTERNATIONAL CORP /DE/ - Form DEFA14A

discontinued operations results for the period.

SYNCOR INTERNATIONAL CORPORATION

SELECTED CASH FLOW DATA FOR CONTINUING OPERATIONS

	NINE MONTHS ENDED SEPTEMBER 30,	
	2002	2001
	(\$ IN 000'S)	
Net Cash Provided By (Used In) Operations.....	\$54,260	\$ 42,613
Less: Capital Additions.....	\$20,741	\$ 32,226
FREE CASH FLOW.....	\$33,519	\$ 10,387
Acquisition of Businesses, Net of Cash Acquired.....	\$ 6,446	\$ 25,415
Total.....	\$27,073	\$ (15,028)

SYNCOR INTERNATIONAL CORPORATION

SELECTED BALANCE SHEET DATA

	SEPTEMBER 30, 2002	JUNE 30, 2002	DECEMBER 31, 2001
	(\$ IN 000'S)		
CONTINUING OPERATIONS:			
Cash, Cash Equiv. and Marketable Securities.....	\$ 38,662	\$ 17,262	\$ 28,855
Accounts Receivables, net.....	\$106,715	\$113,057	\$ 97,003
Inventory.....	\$ 28,875	\$ 28,224	\$ 28,879
Total Current Assets.....	\$197,566	\$180,141	\$172,946
Total Assets.....	\$346,093	\$327,640	\$304,687
Accounts Payable.....	\$ 65,204	\$ 67,549	\$ 62,021
Other Current Liabilities (includes short-term debt).....	\$ 50,611	\$ 69,769	\$ 38,006
Total Current Liabilities.....	\$115,815	\$137,318	\$100,027
Debt (short term and long term):			
Credit Line.....	\$ 9,625	\$ 7,520	\$ 26,122
Other Debt (includes short-term debt).....	\$ 11,238	\$ 25,870	\$ 15,341
Total Outstanding Debt.....	\$ 20,863	\$ 33,390	\$ 41,463
Total Stockholders' Equity.....	\$223,361	\$230,336	\$234,828
Current Ratio.....	1.71	1.31	1.73
DSO.....	50.52	54.34	53.87
DISCONTINUED OPERATIONS:			
Accounts Receivables, net.....	\$ 45,247	\$ 50,016	\$ 58,700
Inventory.....	\$ 1,315	\$ 1,431	\$ 1,751
Total Current Assets.....	\$ 71,054	\$ 68,673	\$ 74,450
Total Assets.....	\$235,794	\$283,541	\$283,154

Edgar Filing: SYNCOR INTERNATIONAL CORP /DE/ - Form DEFA14A

Accounts Payable.....	\$ 2,519	\$ 3,352	\$ 3,832
Other Current Liabilities (includes short-term debt).....	\$ 52,045	\$ 30,762	\$ 26,256
	-----	-----	-----
Total Current Liabilities.....	\$ 54,564	\$ 34,114	\$ 30,088
Debt (short term and long term):			
Credit Line.....	\$130,638	\$141,080	\$143,328
Other Debt (includes short-term debt).....	\$ 46,167	\$ 33,020	\$ 41,906
	-----	-----	-----
Total Outstanding Debt.....	\$176,805	\$174,100	\$185,234
Total Stockholders' (Deficit) Equity.....	\$ (52,621)	\$ (20,278)	\$ (862)
Current Ratio.....	1.30	2.01	2.47
DSO.....	99.29	116.81	111.36

SYNCOR INTERNATIONAL CORPORATION

GOODWILL IMPACT

	NINE MONTHS ENDED SEPTEMBER 30, 2001	THREE MONTHS ENDED SEPTEMBER 30, 2001
	-----	-----
	(\$ IN 000'S)	
First Quarter, 2001.....	\$1,530	\$ 0
Second Quarter, 2001.....	\$1,548	\$ 0
Third Quarter, 2001.....	\$1,372	\$1,372
	-----	-----
Total Goodwill Expense.....	\$4,450	\$1,372
Tax Effect.....	0.60	0.60
	-----	-----
Net Income Effect.....	\$2,670	\$ 823
	=====	=====
Estimated Impact on EPS		
Without Goodwill Amortization:		
Basic Shares Outstanding.....	\$ 0.11	\$ 0.03
Diluted Shares Outstanding.....	\$ 0.10	\$ 0.03
Weighted Average Number of Common Shares Outstanding:		
Basic.....	24,494	24,603
Diluted.....	27,047	27,024

[Syncor Logo]

[Cardinal Health Logo]

NASDAQ: SCOR

NYSE: CAH

FOR IMMEDIATE RELEASE

CONTACT:

Allan Mayer

Sitrick And Company

(310) 788-2850

William Powell

Syncor International Corp.

(818) 737-4702
David Verbraska
Cardinal Health
614-757-3690

CARDINAL HEALTH INITIATES
DISCUSSIONS WITH SYNCOR TO POSSIBLY
MODIFY MERGER AGREEMENT

WOODLAND HILLS, CALIFORNIA AND DUBLIN, OHIO -- NOVEMBER 21, 2002 -- Syncor International Corporation (Nasdaq: SCOR) and Cardinal Health, Inc. (NYSE: CAH) today announced that Cardinal Health has initiated discussions with Syncor regarding the possible modification of the terms of their previously announced merger agreement under which Cardinal Health would acquire Syncor. While the parties intend to continue these discussions, there can be no assurance that such discussions will result in the parties agreeing to any revised terms.

On November 6, 2002, Syncor announced that a newly established special committee of three outside directors, together with outside counsel, had been investigating the propriety of certain payments made by certain of Syncor's international subsidiaries to customers in several foreign countries. Syncor also announced that the special committee would investigate Syncor's other foreign operations. Earlier this week, Syncor announced, among other things, the special committee's findings based on the information it had gathered to date.

Based on the information Syncor has reviewed as of the date hereof with respect to the matters currently under investigation by the special committee, and subject to the terms of any resolution of these matters with the Securities and Exchange Commission (SEC) and the United States Department of Justice (DOJ), Syncor believes that the information it has learned in the investigation would not result in Syncor's failure to

Syncor International Corporation and Cardinal Health, Inc.
CARDINAL HEALTH INITIATES DISCUSSIONS WITH SYNCOR TO POSSIBLY MODIFY MERGER
AGREEMENT
November 21, 2002
Page 2

satisfy the conditions to the existing merger agreement. However, Syncor cannot make a definitive determination as to the impact on the acquisition pending completion of the investigation and resolution of Syncor's discussions with the SEC and DOJ. Cardinal Health has not yet concluded whether the conditions to the transaction will be satisfied and believes that there can be no assurance that the transaction involving the acquisition of Syncor by Cardinal Health will be completed. In light of the foregoing, both companies believe that engaging in discussions regarding a possible modification of certain of the terms of the existing merger agreement is the best course of action at this time.

The existing merger agreement provides for the acquisition of Syncor by Cardinal Health in a stock-for-stock transaction in which Syncor would become a wholly owned subsidiary of Cardinal Health. Terms of the existing merger agreement call for Syncor stockholders to receive .52 Cardinal Health common shares for each outstanding share of Syncor common stock.

ABOUT SYNCOR

SYNCOR INTERNATIONAL CORPORATION is a leading provider of high technology health care services concentrating on nuclear pharmacy services, medical imaging, niche manufacturing and radiotherapy. In the nuclear pharmacy services business, Syncor compounds and dispenses radiopharmaceuticals for diagnostic and therapeutic use by nuclear medicine departments in hospitals and outpatient

Edgar Filing: SYNCOR INTERNATIONAL CORP /DE/ - Form DEFA14A

clinics. Syncor distributes these time-critical pharmaceuticals to more than 7,000 U.S.-based customers through an integrated network of 130 domestic and 19 international nuclear pharmacies. Medical imaging services are provided through an integrated network of 73 domestic and 19 internationally owned or operated facilities. Syncor announced on June 14, 2002 that it intends to exit the U.S. medical imaging business. Syncor also owns or operates ten domestic and two international production facilities for positron emission tomography (PET) radiopharmaceuticals, and is a party to a series of agreements to make PET technology more accessible to healthcare providers and patients nationwide. For more information visit www.syncor.com.

ABOUT CARDINAL HEALTH

CARDINAL HEALTH, INC. is the leading provider of products and services supporting the health care industry. Cardinal Health companies develop, manufacture, package and market products for patient care; develop drug-delivery technologies; distribute pharmaceuticals, medical- surgical and laboratory supplies; and offer; consulting and other services that improve quality and efficiency in health care. Headquartered in Dublin, Ohio, Cardinal Health employs more than 49,000 people on five continents and produces annual revenues of more than \$44 billion.

Except for historical information, all other information in this news release consists of forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, anticipated or implied. The most significant of these uncertainties are described in Syncor's and Cardinal Health's Form 10-K, Form 8-K and Form 10-Q reports (including all amendments to those reports) and exhibits to those reports, and include (but are not limited to) the costs, difficulties, and uncertainties related to the integration of acquired businesses, the loss of one or more key customer or supplier relationships, changes in the distribution patterns or reimbursement rates for health-care products and/or services, the costs and other effects of governmental regulation and legal and administrative proceedings, and general economic and market conditions. Syncor and Cardinal Health undertake no obligation to update or revise any forward-looking statements.

Information regarding the identity of the persons who may, under SEC rules, be deemed to be participants in the solicitation of stockholders of Syncor International Corporation ("Syncor") in connection with the proposed merger, and their interests in the solicitation, is set forth in the definitive proxy statement/prospectus dated October 16, 2002 mailed to Syncor shareholders on October 17, 2002 and filed with the SEC. Cardinal Health, Inc. ("Cardinal Health") has filed a registration statement on Form S-4 in connection with the transaction. Investors and security holders of Syncor are urged to read the definitive proxy statement/prospectus because it contains important information about Cardinal Health, Syncor and the transaction. Investors and security holders may obtain a free copy of the proxy statement/prospectus at the SEC's web site at www.sec.gov. A free copy of the proxy statement/prospectus may also be

Syncor International Corporation and Cardinal Health, Inc.
CARDINAL HEALTH INITIATES DISCUSSIONS WITH SYNCOR TO POSSIBLY MODIFY MERGER
AGREEMENT
November 21, 2002
Page 3

obtained from Cardinal Health or Syncor. Cardinal Health and Syncor and their respective executive officers and directors may be deemed to be participants in the solicitation of proxies from the stockholders of Syncor in favor of the

Edgar Filing: SYNCOR INTERNATIONAL CORP /DE/ - Form DEFA14A

transaction. In addition to the registration statement on Form S-4 filed by Cardinal Health in connection with the transaction, and the proxy statement/prospectus mailed to the stockholders of Syncor in connection with the transaction, each of Cardinal Health and Syncor file annual, quarterly and special reports, proxy and information statements, and other information with the SEC. Investors may read and copy any of these reports, statements and other information at the SEC's public reference room located at 450 5th Street, N.W., Washington, D.C., 20549. Investors should call the SEC at 1-800-SEC-0330 for further information. The reports, statements and other information filed by Cardinal Health and Syncor with the SEC are also available for free at the SEC's web site at www.sec.gov. A free copy of these reports, statements and other information may also be obtained from Cardinal Health or Syncor. Investors should read the proxy statement/prospectus carefully before making any voting or investment decision.

[Syncor Logo]

[Cardinal Health Logo]

NASDAQ: SCOR

NYSE: CAH

FOR IMMEDIATE RELEASE

CONTACT:

Allan Mayer

Sitrick And Company

(310) 788-2850

William Powell

Syncor International Corp.

(818) 737-4702

David Verbraska

Cardinal Health

(614) 757-3690

SYNCOR AND CARDINAL HEALTH ANNOUNCE AMENDMENT TO
MERGER AGREEMENT TO EXTEND TERMINATION DATE

WOODLAND HILLS, CALIFORNIA AND DUBLIN, OHIO -- NOVEMBER 22, 2002 -- Syncor International Corporation (Nasdaq: SCOR) and Cardinal Health, Inc. (NYSE: CAH) today announced that they have agreed to amend their previously announced merger agreement to extend the date after which either party may unilaterally elect to terminate the transaction from December 31, 2002, to January 15, 2003, subject to the terms of the merger agreement. The amendment does not affect any terms of the merger agreement other than the termination provisions.

On November 21, 2002, Syncor and Cardinal Health announced that Cardinal Health had initiated discussions with Syncor regarding the possible modification of the terms of their previously announced merger agreement under which Cardinal Health would acquire Syncor. The purpose of the amendment to the termination date is to provide the parties with further time to continue these discussions. While the parties intend to continue these discussions, there can be no assurance that such discussions will result in the parties agreeing to any revised terms. Cardinal Health has previously stated that it has not yet concluded whether the conditions to the transaction will be satisfied and that "there can be no assurance that the transaction involving the acquisition of Syncor by Cardinal Health will be completed."

Syncor also today announced that it will be mailing to its stockholders a

Edgar Filing: SYNCOR INTERNATIONAL CORP /DE/ - Form DEFA14A

supplemental notice of postponement of its special meeting of stockholders to consider approval of the merger agreement with Cardinal Health. As previously announced, the postponed meeting will now be held on December 6, 2002.

Syncor International Corporation and Cardinal Health, Inc.

SYNCOR AND CARDINAL HEALTH ANNOUNCE AMENDMENT TO MERGER AGREEMENT TO EXTEND TERMINATE DATE

November 22, 2002

Page 2

Syncor intends to convene the postponed special meeting on December 6 solely for the purpose of adjourning the meeting to a later time, date and place so that additional information can be provided to stockholders.

ABOUT SYNCOR

SYNCOR INTERNATIONAL CORPORATION is a leading provider of high technology health care services concentrating on nuclear pharmacy services, medical imaging, niche manufacturing and radiotherapy. In the nuclear pharmacy services business, Syncor compounds and dispenses radiopharmaceuticals for diagnostic and therapeutic use by nuclear medicine departments in hospitals and outpatient clinics. Syncor distributes these time-critical pharmaceuticals to more than 7,000 U.S.-based customers through an integrated network of 130 domestic and 19 international nuclear pharmacies. Medical imaging services are provided through an integrated network of 73 domestic and 19 internationally owned or operated facilities. Syncor announced on June 14, 2002 that it intends to exit the U.S. medical imaging business. Syncor also owns or operates ten domestic and two international production facilities for positron emission tomography (PET) radiopharmaceuticals, and is a party to a series of agreements to make PET technology more accessible to healthcare providers and patients nationwide. For more information visit www.syncor.com.

ABOUT CARDINAL HEALTH

CARDINAL HEALTH, INC. is the leading provider of products and services supporting the health care industry. Cardinal Health companies develop, manufacture, package and market products for patient care; develop drug-delivery technologies; distribute pharmaceuticals, medical-surgical and laboratory supplies; and offer consulting and other services that improve quality and efficiency in health care. Headquartered in Dublin, Ohio, Cardinal Health employs more than 49,000 people on five continents and produces annual revenues of more than \$44 billion.

Except for historical information, all other information in this news release consists of forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, anticipated or implied. The most significant of these uncertainties are described in Syncor's and Cardinal Health's Form 10-K, Form 8-K and Form 10-Q reports (including all amendments to those reports) and exhibits to those reports, and include (but are not limited to) the costs, difficulties, and uncertainties related to the integration of acquired businesses, the loss of one or more key customer or supplier relationships, changes in the distribution patterns or reimbursement rates for health-care products and/or services, the costs and other effects of governmental regulation and legal and administrative proceedings, and general economic and market conditions. Syncor and Cardinal Health undertake no obligation to update or revise any forward-looking statements.

Information regarding the identity of the persons who may, under SEC rules, be

Edgar Filing: SYNCOR INTERNATIONAL CORP /DE/ - Form DEFA14A

deemed to be participants in the solicitation of stockholders of Syncor International Corporation ("Syncor") in connection with the proposed merger, and their interests in the solicitation, is set forth in the definitive proxy statement/prospectus dated October 16, 2002 mailed to Syncor shareholders on October 17, 2002 and filed with the SEC. Cardinal Health, Inc. ("Cardinal Health") has filed a registration statement on Form S-4 in connection with the transaction. Investors and security holders of Syncor are urged to read the definitive proxy statement/prospectus because it contains important information about Cardinal Health, Syncor and the transaction. Investors and security holders may obtain a free copy of the proxy statement/prospectus at the SEC's web sit at www.sec.gov. A free copy of the proxy statement/prospectus may also be obtained from Cardinal Health or Syncor. Cardinal Health and Syncor and their respective executive officers and directors may be deemed to be participants in the solicitation of proxies from the stockholders of Syncor in favor of the transaction. In addition to the registration statement on Form S-4 filed by Cardinal Health in connection with the transaction, and the proxy statement/prospectus mailed to the stockholders of Syncor in connection with the transaction, each of Cardinal Health and Syncor file annual, quarterly and special reports, proxy and information statements, and other information with the SEC. Investors may read and copy any of these reports, statements and other information at the SEC's public reference room located at 450 5th Street, N.W., Washington, D.C., 20549. Investors should call the SEC at 1-800-SEC-0330 for further information. The reports, statements and other information filed by Cardinal Health and Syncor with the SEC are also available for free at the SEC's web site at www.sec.gov. A free copy of these reports, statements and other information may also be obtained from Cardinal Health or Syncor. Investors should read the proxy statement/prospectus carefully before making any voting or investment decision.

SPECIAL MEETING OF STOCKHOLDERS OF
SYNCOR INTERNATIONAL CORPORATION

December 6, 2002

Co. #

Acct. #

/PROXY VOTING INSTRUCTIONS/

TO VOTE BY MAIL

Please date, sign and mail your proxy card in the envelope provided as soon as possible.

TO VOTE BY TELEPHONE (TOUCH-TONE PHONE ONLY)

Please call toll-free 1-800-PROXIES and follow the instructions. Have your control number and the proxy card available when you call.

TO VOTE BY INTERNET

Please access the web page at "www.voteproxy.com" and follow the on-screen instructions. Have your control number available when you access the web page.

YOUR CONTROL NUMBER IS [RIGHT ARROW] / /

[DOWN ARROW] Please Detach and Mail in the Envelope Provided [DOWN ARROW]

Please mark your

Edgar Filing: SYNCOR INTERNATIONAL CORP /DE/ - Form DEFA14A

A /X/ votes as in this example.

- 1. MERGER AGREEMENT. To approve the Agreement and Plan of Merger, dated as of June 14, 2002, by and among Syncor, Cardinal Health, Inc. and Mudhen Merger Corp. pursuant to which Mudhen Merger Corp. will be merged with and into Syncor

FOR	AGAINST	ABSTAIN
/ /	/ /	/ /

- 2. ADJOURNMENT. To adjourn the Special Meeting, if necessary, to permit further solicitation of proxies in the event there are not sufficient votes at the time of the Special Meeting to approve the merger agreement proposal

/ /	/ /	/ /
-----	-----	-----

In their discretion, the proxies named above are authorized to vote upon such other matters as may properly come before the Special Meeting and any adjournment or postponement of the Special Meeting. If you do not sign and return a proxy card, or vote by telephone or through the internet or attend the Special Meeting, your shares of Syncor Common Stock cannot be voted. If no instructions are given, this proxy will be voted FOR both proposals.

All previous proxies given by the undersigned to vote at the Special Meeting or at any adjournment or postponement of the Special Meeting are hereby revoked, and receipt of notice of the Special Meeting and of the accompanying Proxy Statement is hereby acknowledged.

Your control number is _____

IMPORTANT -- PLEASE COMPLETE, SIGN, DATE AND RETURN PROMPTLY.

Date: 2002

Signature (Signature, if jointly held) (Title)

NOTE: Please sign your name exactly as it appears hereon. Joint owners should each sign. When signing as attorney, executor, administrator, trustee or guardian, please give your full title as such. If signing on behalf of a corporation, please sign in full corporate name by the President or other authorized officer(s) of the corporation. If signing on behalf of a partnership, please sign in full partnership name by authorized person(s) of the partnership.

PROXY

THE PROXY IS SOLICITED BY THE BOARD OF DIRECTORS OF SYNCOR INTERNATIONAL CORPORATION FOR THE SPECIAL MEETING OF

Edgar Filing: SYNCOR INTERNATIONAL CORP /DE/ - Form DEFA14A

SYNCOR INTERNATIONAL CORPORATION STOCKHOLDERS.

The undersigned hereby appoints Bernard Puckett and Robert G. Funari, and each of them, with full power of substitution and resubstitution, attorneys and proxies of the undersigned to vote all of the outstanding shares of common stock, par value \$0.05 per share, of Syncor International Corporation ("Syncor") ("Syncor Common Stock") that the undersigned is entitled to vote, and with all the power that the undersigned would possess. If personally present, at the special meeting of Syncor stockholders to be held on December 6, 2002 (the "Special Meeting"), or at any adjournment or postponement of the Special Meeting, on the following matters:

(CONTINUED, AND TO BE SIGNED, ON OTHER SIDE)

Please Detach and Mail in the Envelope Provided

Please mark your
A [X] votes as in this
example.

- | | FOR | AGAINST | ABSTAIN |
|--|-----|---------|---------|
| 1. MERGER AGREEMENT. To approve the Agreement and Plan of Merger, dated as of June 14, 2002, by and among Syncor, Cardinal Health, Inc. and Mudhen Merger Corp. pursuant to which Mudhen Merger Corp. will be merged with and into Syncor. | [] | [] | [] |
| 2. ADJOURNMENT. To adjourn the Special Meeting, if necessary, to permit further solicitation of proxies in the event there are not sufficient votes at the time of the Special Meeting to approve the merger agreement proposal. | [] | [] | [] |

In their discretion, the proxies named above are authorized to vote upon such other matters as may properly come before the Special Meeting and any adjournment or postponement of the Special Meeting. If you do not sign and return a proxy card, or vote by telephone or through the internet, or attend the Special Meeting, your shares of Syncor Common Stock cannot be voted. If no instructions are given, this proxy will be voted FOR both proposals.

All previous proxies given by the undersigned to vote at the Special Meeting or at any adjournment or postponement of the Special Meeting are hereby revoked, and receipt of notice of the Special Meeting and of the accompanying Proxy Statement is hereby acknowledged.

Your control number is: _____

IMPORTANT-PLEASE COMPLETE, SIGN, DATE AND RETURN PROMPTLY.

Date: _____, 2002

Edgar Filing: SYNCOR INTERNATIONAL CORP /DE/ - Form DEFA14A

Signature (Signature, if jointly held) (Title)

NOTE: Please sign your name exactly as it appears hereon. Joint owners should each sign. When signing as attorney, executor, administrator, trustee or guardian, please give your full title as such. If signing on behalf of a corporation, please sign in full corporate name by the President or other authorized officer(s) of the corporation. If signing on behalf of a partnership, please sign in full partnership name by authorized person(s) of the partnership.

PLEASE DATE, SIGN AND MAIL YOUR
PROXY CARD BACK AS SOON AS POSSIBLE!

SPECIAL MEETING OF STOCKHOLDERS
SYNCOR INTERNATIONAL CORPORATION

DECEMBER 6, 2002

- PLEASE DETACH AND MAIL IN THE ENVELOPE PROVIDED-

PLEASE MARK
A [X] YOUR VOTES
AS IN THE
EXAMPLE

- | | | FOR | AGAINST | ABSTAIN |
|---|---|-----|---------|---------|
| 1 | MERGER AGREEMENT. To approve the Agreement and Plan of Merger, dated as of June 14, 2002, by and among Syncor, Cardinal Health, Inc. and Mudhen Merger Corp. pursuant to which Mudhen Merger Corp. will be merged with and into Syncor. | [] | [] | [] |
| 2 | ADJOURNMENT. To adjourn the Special Meeting, if necessary, to permit further solicitation of proxies in the event there are not sufficient votes at the time of the Special Meeting to approve the merger agreement proposal. | [] | [] | [] |

In their discretion, the proxies named above are authorized to vote upon such other matters as may properly come before the Special Meeting and any adjournment or postponement of the Special Meeting. If you do not sign and return a proxy card, or vote by telephone or through the internet or attend the Special Meeting, your shares of Syncor Common Stock cannot be voted. If no instructions are given, this proxy will be voted FOR both proposals.

All previous proxies given by the undersigned to vote at the Special Meeting or at any adjournment or postponement of the Special Meeting are hereby revoked, and receipt of notice of the Special Meeting and of the accompanying Proxy Statement

Edgar Filing: SYNCOR INTERNATIONAL CORP /DE/ - Form DEFA14A

is hereby acknowledged.

Your control number is:

IMPORTANT - PLEASE COMPLETE, SIGN, DATE AND RETURN PROMPTLY

DATE: _____, 2002

Signature (Signature, if jointly held) (Title)

NOTE: Please sign your name exactly as it appears hereon. Joint owners should each sign. When signing as attorney, executor, administrator, trustee or guardian, please give your full title as such. If signing on behalf of a corporation, please sign in full corporate name by the President or other authorized officer(s) of the corporation. If signing on behalf of a partnership, please sign in full partnership name by authorized person(s) of the partnership.
